



## Company Overview

iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBio Technology platform.

The iBio Technology platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines.

## iBio, Inc. Announces NYSE American Acceptance of Plan of Compliance

Aug 22 2018, 4:10 PM EDT

## iBio Establishes Strategic Commercial Relationship with CC-Pharming Ltd. of Beijing, China

Jul 9 2018, 8:00 AM EDT

## iBio, Inc. Closes \$16,000,000 Public Offering

Jun 26 2018, 6:59 PM EDT

## Stock Overview

Symbol	IBIO
Exchange	NYSE American
Shares OS	18,336,792
Market Cap	\$16.32M
Last Price	\$0.89
52-Week	\$0.6001 - \$3.999

09/21/2018 04:10 PM EDT

## Investor Relations

iBio, Inc.  
T: 302-355-9452  
[ir@ibioinc.com](mailto:ir@ibioinc.com)

## Management Team

### Robert B. Kay

Executive Chairman and Chief Executive Officer

### Robert L. Erwin

President

### R. Barry Holtz, Ph.D.

President, iBio CDMO

### James P. Mullaney

Chief Financial Officer

### Terence E. Ryan, Ph.D.

Chief Scientific Officer

### James Abbey, Ph.D.

Vice President of Strategic Business Development

### Wayne P. Fitzmaurice, Ph.D.

Vice President, Intellectual Property

## iBio Inc.

600 Madison Avenue  
Suite 1601  
New York, NY 10022

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.